Cilixyl® is the first product on the market with proven efficacy to treat dry nose in an open and double-blind test. It reactivates the damaged nasal mucosal soft tissue and reduces the nose’s soft tissue tendency for inflammation. Prevents long-term damages caused by dry, irritated nose and restores the nasal mucosa and hence the mucociliary function. Diminishes the chance of bacterial infection (Corynebacterium) and provides both subjective improvement and objective clinical treatment.